Rapid Micro Biosystems, Inc.
NASDAQ•RPID
CEO: Mr. Robert G. Spignesi Jr.
セクター: Healthcare
業種: Medical - Devices
上場日: 2021-07-15
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
連絡先情報
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, 01854, United States
978-349-3200
時価総額
$193.25M
PER (TTM)
-4.4
29.5
配当利回り
--
52週高値
$4.94
52週安値
$1.86
52週レンジ
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025
財務ダッシュボード
Q3 2025 データ
売上高
$7.84M+3.08%
直近4四半期の推移
EPS
-$0.25-3.85%
直近4四半期の推移
フリーCF
-$9.12M+3.41%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Strong Service Revenue Growth Service revenue reached $8.188M for nine months, showing 29.4% increase; recurring revenue up 17.4% to $13.226M.
Net Loss Reduction Achieved Nine-month net loss narrowed to $34.626M, a 7.0% improvement from prior period loss of $37.223M; operating loss improved 11.4%.
Growth Direct System Placements Cumulative systems placed reached 174, increasing 11.5% over prior period; validated systems grew 14.3% to 152 units.
New Debt Facility Secured Entered Loan and Security Agreement in August 2025, drawing $20.0M tranche to support operations and future growth initiatives.
リスク要因
Continued Operating Losses Expected Incurred $11.5M net loss Q3 2025; accumulated deficit is $509.9M; expects continued losses near term without financing.
Platform Commercial Success Risk Business depends on Growth Direct platform acceptance; failure to gain market traction risks financial condition severely.
Supplier Dependency Vulnerability Manufacturing relies on third-party suppliers, including single-source components, risking shortages and price fluctuations impacting costs.
Future Capital Requirements Risk If performance expectations are not realized, company may need to raise additional capital via equity or debt financing to sustain operations.
見通し
Drive Global Customer Adoption Plan to increase global adoption of Growth Direct platform via direct and indirect sales in North America, Europe, and Asia-Pacific regions.
Innovate Platform Applications Intent to invest in R&D for platform enhancements, new product formats, and expanding applications like the Rapid Sterility application.
Cash Sufficient for Twelve Months Existing cash, cash equivalents, and investments estimated sufficient to fund operating expenses and capital expenditures for at least twelve months.
Target Gross Margin Expansion Focus areas include reducing product costs, increasing manufacturing efficiency, and expanding higher margin products and services offerings.
同業比較
売上高 (TTM)
$99.66M
$77.36M
$71.61M
粗利益率 (最新四半期)
92.4%
87.3%
83.5%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| SGHT | $286.04M | -7.5 | -55.7% | 35.0% |
| PROF | $225.91M | -5.6 | -86.8% | 0.7% |
| RPID | $193.25M | -4.4 | -73.9% | 28.6% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-1.6%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年3月12日
EPS:-$0.23
|売上高:$10.93M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし